Brief: Can Fite Biopharma Ltd's Drug Receives Recognition From American Society Of Clinical Oncology For Inhibition Of Pancreatic Cancer
30/05/2023 13:04
May 30 (Reuters) - Can Fite Biopharma Ltd CANF.TA :
* NAMODENOSON'S INHIBITION OF PANCREATIC CARCINOMA RECEIVES
RECOGNITION FROM AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO)
* CAN-FITE TO INITIATE PHASE 2A PANCREATIC CANCER STUDY
Source text for Eikon: ID:nBw9fbTxsa
Further company coverage: CANF.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Can Fite Biopharma
See all newsBrief: Corrected-Can Fite Biopharma Ltd Files For Offering Of Up To 6.6 mln Ordinary Shares By Selling Shareholders
Can-Fite BioPharma rises after longer-than-anticipated overall survival in ongoing liver cancer study
Can-Fite BioPharma reports longer-than-anticipated overall survival in ongoing liver cancer study
Brief: Can Fite Biopharma Can-Fite Submits Phase 2 Study Protocol For Piclidenoson In Lowe Syndrome
Can-Fite rises as skin drug study reaches interim analysis stage